Noorjahan Mohammed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Noorjahan Mohammed has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Siraj Ahmed Khan
Department of Biochemistry, Nizam’s Institute of Medical Sciences, Panjagutta, Hyderabad, Telangana, India
3 shared publicationsSree Bhushan Raju
Department of Nephrology, Nizams Institute of Medical Science, Hyderabad, Telangana, India
3 shared publicationsMaira Fatima
Department of Biochemistry, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
2 shared publicationsOruganti Sai Satish
Department of Cardiology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
2 shared publications- Priscilla Abraham Chandran
Department of Biochemistry, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Andhra Pradesh 500082, India
2 shared publications Priyanka Das
Department of Biochemistry, Nizam’s Institute of Medical Sciences, Panjagutta, Hyderabad, Telangana, India
2 shared publications
Latest Publications
- Open Access
- 14 January 2026
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 18, 1-7
Evaluation of the fibroblast growth factor-23 and bone minerals in renal transplant recipients: A follow-up study
Objectives: The objective of the study is to assess fibroblast growth factor-23 (FGF23) and its association with bone minerals in renal transplant recipients. Materials and Methods: A prospective longitudinal study comprising 32 end-stage renal disease cases awaiting renal transplant was followed up for three months post-transplant. Statistical analysis: Data were analyzed using appropriate tests such as the Freidman test, Pearson correlation with Statistical Package for the Social Sciences 20, and GraphPad Prism 7. P st week and stabilized thereafter. Glomerular filtration rate (GFR) increased post-transplant immediately and stabilized in the following months. Calcium levels improved by 1 month post-transplant and stabilized thereafter. Phosphorus decreased in the immediate post-transplant period, and then a slight increase was noted. GFR has shown a negative correlation ( r = -0.24, P < 0.01) with FGF23 when pre and post-transplant samples were considered together. Phosphorus showed a positive correlation ( r = 0.3, P < 0.001) with FGF23. Pre-transplant ( r = 0.36, P < 0.044) and 3 months post-transplant ( r = 0.44, P = 0.025), FGF23 levels showed a positive correlation with phosphorus. FGF23 levels increase significantly post-transplantation within three months of stable graft function. An increase in phosphorus levels within the normal range was noted, with a significant positive correlation with FGF23. Conclusions: Greater information about aberrant FGF23 and its effects on bone minerals is necessary to understand whether efforts to restore it after transplant are desirable.
- 14 January 2026
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 18, 1-7
Open AccessEvaluation of the fibroblast growth factor-23 and bone minerals in renal transplant recipients: A follow-up study
Objectives: The objective of the study is to assess fibroblast growth factor-23 (FGF23) and its association with bone minerals in renal transplant recipients. Materials and Methods: A prospective longitudinal study comprising 32 end-stage renal disease cases awaiting renal transplant was followed up for three months post-transplant. Statistical analysis: Data were analyzed using appropriate tests such as the Freidman test, Pearson correlation with Statistical Package for the Social Sciences 20, and GraphPad Prism 7. P st week and stabilized thereafter. Glomerular filtration rate (GFR) increased post-transplant immediately and stabilized in the following months. Calcium levels improved by 1 month post-transplant and stabilized thereafter. Phosphorus decreased in the immediate post-transplant period, and then a slight increase was noted. GFR has shown a negative correlation ( r = -0.24, P < 0.01) with FGF23 when pre and post-transplant samples were considered together. Phosphorus showed a positive correlation ( r = 0.3, P < 0.001) with FGF23. Pre-transplant ( r = 0.36, P < 0.044) and 3 months post-transplant ( r = 0.44, P = 0.025), FGF23 levels showed a positive correlation with phosphorus. FGF23 levels increase significantly post-transplantation within three months of stable graft function. An increase in phosphorus levels within the normal range was noted, with a significant positive correlation with FGF23. Conclusions: Greater information about aberrant FGF23 and its effects on bone minerals is necessary to understand whether efforts to restore it after transplant are desirable.
- Open Access
- 25 October 2024
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 35, 539-544
Hepcidin, GDF-15 and their Impact on Iron Metabolism in CKD
Background: Anemia is an important complication in chronic kidney disease (CKD). We studied the diagnostic accuracy of hepcidin and growth differentiation factor-15 (GDF-15) as early markers of iron deficiency anemia (IDA) in non-dialysis (ND-CKD) patients. Materials and Methods: This was a cross-sectional, case-control study comprising 100 cases of CKD (newly diagnosed and non-dialyzed) and 40 healthy controls. Serum levels of hepcidin and GDF-15 were estimated using ELISA-based assays. Receiver operator characteristics were used to evaluate the diagnostic validity of hepcidin and GDF-15 for absolute and functional iron deficiency anemia. Results: About 33% of the cases were females with a mean age of 47.64 (± 13.68) years. The predictive value of hepcidin for diagnosing functional IDA in CKD was found to be 69.1% (95% CI: 52.5% to 82.7%), and that of GDF-15 was found to be 68.8% (95% CI: 52.6% to 82.1%). Hepcidin significantly correlated with hemoglobin (r = 0.278, p = 0.005) and serum iron (r = 0.222; p = 0.025). GDF-15 positively correlated with ferritin (r = 0.346, p < 0.0001) and hsCRP (r = 0.223, p = 0.0088) and negatively correlated with eGFR (r = -0.462, p < 000001), Hb (r = -0.481, p < 0.00001) and TIBC (r = -0.353, p < 0.0001). Conclusion: Hepcidin and GDF-15 could predict functional IDA in our patients but not absolute IDA.
- 25 October 2024
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 35, 539-544
Open AccessHepcidin, GDF-15 and their Impact on Iron Metabolism in CKD
Background: Anemia is an important complication in chronic kidney disease (CKD). We studied the diagnostic accuracy of hepcidin and growth differentiation factor-15 (GDF-15) as early markers of iron deficiency anemia (IDA) in non-dialysis (ND-CKD) patients. Materials and Methods: This was a cross-sectional, case-control study comprising 100 cases of CKD (newly diagnosed and non-dialyzed) and 40 healthy controls. Serum levels of hepcidin and GDF-15 were estimated using ELISA-based assays. Receiver operator characteristics were used to evaluate the diagnostic validity of hepcidin and GDF-15 for absolute and functional iron deficiency anemia. Results: About 33% of the cases were females with a mean age of 47.64 (± 13.68) years. The predictive value of hepcidin for diagnosing functional IDA in CKD was found to be 69.1% (95% CI: 52.5% to 82.7%), and that of GDF-15 was found to be 68.8% (95% CI: 52.6% to 82.1%). Hepcidin significantly correlated with hemoglobin (r = 0.278, p = 0.005) and serum iron (r = 0.222; p = 0.025). GDF-15 positively correlated with ferritin (r = 0.346, p < 0.0001) and hsCRP (r = 0.223, p = 0.0088) and negatively correlated with eGFR (r = -0.462, p < 000001), Hb (r = -0.481, p < 0.00001) and TIBC (r = -0.353, p < 0.0001). Conclusion: Hepcidin and GDF-15 could predict functional IDA in our patients but not absolute IDA.
- Open Access
- 1 October 2023
- Published by Medknow in Journal of Clinical and Scientific Research
- Vol. 12 (4) , 279-284
N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein and ferritin in predicting the functional outcome in stroke patients
Background: Biomarkers that predict the outcome of stroke are critical for treatment, considering them to be a valuable adjunct to routine clinical examination and imaging data. Methods: Thirty-one patients admitted with stroke along with 30 controls were included in the study. Patients were divided into ischaemic and haemorrhagic stroke groups based on radiological findings. The study group was evaluated within 48 h of symptom onset for clinical stroke severity (Scandinavian Stroke Scale [SSS] and National Institute of Health Stroke Scale). Functional status before the stroke (modified Rankin Scale [mRS]) and at discharge was evaluated. The association of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP) and serum ferritin concentrations with stroke severity and functional outcomes at discharge in acute ischaemic and haemorrhagic stroke patients. Results: The median NT-proBNP, hsCRP and ferritin serum concentrations were significantly high for cases when compared to controls (P < 0.05). However, serum concentrations of NT-proBNP, hsCRP and ferritin were not significantly different when ischaemic and haemorrhagic stroke patients were compared. HsCRP showed a negative correlation with SSS score on admission and showed a positive correlation with mRS at discharge. In multivariate adjusted regression models, hsCRP remained associated with worse functional outcomes at discharge. Conclusions: In acute stroke patients, elevated concentration of hsCRP is associated with greater clinical stroke severity and worse functional outcomes at discharge. Hence, it can be used along with computed tomography scan/magnetic resonance imaging for assessment of stroke severity.
- 1 October 2023
- Published by Medknow in Journal of Clinical and Scientific Research
- Vol. 12 (4) , 279-284
Open AccessN-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein and ferritin in predicting the functional outcome in stroke patients
Background: Biomarkers that predict the outcome of stroke are critical for treatment, considering them to be a valuable adjunct to routine clinical examination and imaging data. Methods: Thirty-one patients admitted with stroke along with 30 controls were included in the study. Patients were divided into ischaemic and haemorrhagic stroke groups based on radiological findings. The study group was evaluated within 48 h of symptom onset for clinical stroke severity (Scandinavian Stroke Scale [SSS] and National Institute of Health Stroke Scale). Functional status before the stroke (modified Rankin Scale [mRS]) and at discharge was evaluated. The association of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP) and serum ferritin concentrations with stroke severity and functional outcomes at discharge in acute ischaemic and haemorrhagic stroke patients. Results: The median NT-proBNP, hsCRP and ferritin serum concentrations were significantly high for cases when compared to controls (P < 0.05). However, serum concentrations of NT-proBNP, hsCRP and ferritin were not significantly different when ischaemic and haemorrhagic stroke patients were compared. HsCRP showed a negative correlation with SSS score on admission and showed a positive correlation with mRS at discharge. In multivariate adjusted regression models, hsCRP remained associated with worse functional outcomes at discharge. Conclusions: In acute stroke patients, elevated concentration of hsCRP is associated with greater clinical stroke severity and worse functional outcomes at discharge. Hence, it can be used along with computed tomography scan/magnetic resonance imaging for assessment of stroke severity.
- Open Access
- 17 August 2022
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (01) , 020-024
Evaluation of Serum Mammaglobin as an Alternative Biomarker in the Diagnosis of Breast Tumors
Introduction Breast cancer is the most common cancer in women in India and accounts for 14% of all cancers in women. Rise in mortality is due to lack of awareness and proper screening. Mammography and presently available serum biomarkers have low sensitivity and specificity. In our quest to identify a better biomarker, we studied mammaglobin (MAM) in patients with breast cancer and benign breast tumors. Aim To evaluate serum mammaglobin in breast cancer patients and compare it with benign breast tumor patients and healthy controls. To compare it with existing biomarkers serum carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA 15–3). Materials and methods: This is a cross-sectional, case–control study of 77 subjects, of which 27 were breast cancer patients, 20 benign breast tumor patients, and 30 healthy controls. Serum CEA and CA15–3 were estimated by electrochemiluminescence immunoassay (ECLIA) and mammaglobin (MAM) by enzyme-linked immunosorbent assay (ELISA). Results Mammaglobin and CEA levels were elevated in breast cancer patients, followed by benign breast tumors when compared with controls (P < 0.000001). Mammaglobin showed 81.5% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 88.9% negative predictive value (NPV). CEA showed 88.9% sensitivity, 82.5% specificity, 77.4% PPV, and 91.7% NPV. The area under the curve was the highest for MAM (0.892), followed by CEA (0.889) and CA 15–3 (0.555). CA15–3 showed poor diagnostic efficacy. Combined receiver operating characteristic (ROC) curve of the biomarkers MAM and CEA had an AUC of 0.913. Conclusion Mammaglobin proved to be an efficacious biomarker in diagnosing breast cancer.
- 17 August 2022
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 15 (01) , 020-024
Open AccessEvaluation of Serum Mammaglobin as an Alternative Biomarker in the Diagnosis of Breast Tumors
Introduction Breast cancer is the most common cancer in women in India and accounts for 14% of all cancers in women. Rise in mortality is due to lack of awareness and proper screening. Mammography and presently available serum biomarkers have low sensitivity and specificity. In our quest to identify a better biomarker, we studied mammaglobin (MAM) in patients with breast cancer and benign breast tumors. Aim To evaluate serum mammaglobin in breast cancer patients and compare it with benign breast tumor patients and healthy controls. To compare it with existing biomarkers serum carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA 15–3). Materials and methods: This is a cross-sectional, case–control study of 77 subjects, of which 27 were breast cancer patients, 20 benign breast tumor patients, and 30 healthy controls. Serum CEA and CA15–3 were estimated by electrochemiluminescence immunoassay (ECLIA) and mammaglobin (MAM) by enzyme-linked immunosorbent assay (ELISA). Results Mammaglobin and CEA levels were elevated in breast cancer patients, followed by benign breast tumors when compared with controls (P < 0.000001). Mammaglobin showed 81.5% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 88.9% negative predictive value (NPV). CEA showed 88.9% sensitivity, 82.5% specificity, 77.4% PPV, and 91.7% NPV. The area under the curve was the highest for MAM (0.892), followed by CEA (0.889) and CA 15–3 (0.555). CA15–3 showed poor diagnostic efficacy. Combined receiver operating characteristic (ROC) curve of the biomarkers MAM and CEA had an AUC of 0.913. Conclusion Mammaglobin proved to be an efficacious biomarker in diagnosing breast cancer.
- Open Access
- 15 February 2022
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 14 (03) , 253-259
Association of Serum Cyclophilin A Levels with Severity of Coronary Artery Disease
Objective The disequilibrium between oxidant and antioxidant systems causes oxidative stress. Further, it disrupts the cell and releases reactive oxygen species (ROS), which in turn damages the vascular functions. Cyclophilin A (CypA), an immunophilin, is released in a highly regulated manner from vascular smooth muscle cells and multiplies the deleterious effects of ROS, associated with cardiovascular diseases. Thus, the aim of the present study is to correlate serum CypA levels with the severity of coronary artery disease (CAD).Materials and Methods Study participants composed of 103 adult subjects, among whom 73 subjects were cases who were diagnosed as CAD angiographically. Thirty years of age and gender-matched subjects were taken as controls. The cases were further divided into single, double, and triple vessel disease subgroups. Blood samples were collected for the estimation of serum CypA, malondialdehyde (MDA), high-sensitive C-reactive protein (hsCRP), lipid profile, and plasma-glycated hemoglobin (HbA1C) by relevant biochemical methods.Statistical Analysis The analysis was done using SPSS version 25. The data were expressed as median/mean and interquartile range/standard error. The groups were compared using the Mann–Whitney U-test and the Kruskal–Wallis test. p-Value less than 0.05 was considered statistically significant. Comparison of area under the curve (AUC) in receiver operating characteristic (ROC) curves was performed. A correlation was done by Spearman rank correlation.Results The mean levels of serum CypA, hsCRP, and MDA in cases were significantly higher than those of controls (38 vs. 27 ng/mL, 18 vs. 5.1 mg/L, and 26 vs. 14 nmol/mL, p < 0.001). A positive correlation was observed between serum levels of CypA versus hsCRP and CypA versus MDA (r = 0.36 p = 0.00, r = 0.52, p = 0.00). At cut-off values greater than 33 ng/mL and 2.1 mg/L, serum CypA and hsCRP have 71% sensitivity, 93% specificity (AUC = 0.83), 84% sensitivity, and 70% specificity (AUC = 0.78) respectively. The number of occluded vessels was positively correlated with both CypA and hsCRP. Also, Serum CypA showed a significant positive correlation with HbA1C.Conclusion Serum CypA can be used as a valuable biomarker for CAD.
- 15 February 2022
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 14 (03) , 253-259
Open AccessAssociation of Serum Cyclophilin A Levels with Severity of Coronary Artery Disease
Objective The disequilibrium between oxidant and antioxidant systems causes oxidative stress. Further, it disrupts the cell and releases reactive oxygen species (ROS), which in turn damages the vascular functions. Cyclophilin A (CypA), an immunophilin, is released in a highly regulated manner from vascular smooth muscle cells and multiplies the deleterious effects of ROS, associated with cardiovascular diseases. Thus, the aim of the present study is to correlate serum CypA levels with the severity of coronary artery disease (CAD).Materials and Methods Study participants composed of 103 adult subjects, among whom 73 subjects were cases who were diagnosed as CAD angiographically. Thirty years of age and gender-matched subjects were taken as controls. The cases were further divided into single, double, and triple vessel disease subgroups. Blood samples were collected for the estimation of serum CypA, malondialdehyde (MDA), high-sensitive C-reactive protein (hsCRP), lipid profile, and plasma-glycated hemoglobin (HbA1C) by relevant biochemical methods.Statistical Analysis The analysis was done using SPSS version 25. The data were expressed as median/mean and interquartile range/standard error. The groups were compared using the Mann–Whitney U-test and the Kruskal–Wallis test. p-Value less than 0.05 was considered statistically significant. Comparison of area under the curve (AUC) in receiver operating characteristic (ROC) curves was performed. A correlation was done by Spearman rank correlation.Results The mean levels of serum CypA, hsCRP, and MDA in cases were significantly higher than those of controls (38 vs. 27 ng/mL, 18 vs. 5.1 mg/L, and 26 vs. 14 nmol/mL, p < 0.001). A positive correlation was observed between serum levels of CypA versus hsCRP and CypA versus MDA (r = 0.36 p = 0.00, r = 0.52, p = 0.00). At cut-off values greater than 33 ng/mL and 2.1 mg/L, serum CypA and hsCRP have 71% sensitivity, 93% specificity (AUC = 0.83), 84% sensitivity, and 70% specificity (AUC = 0.78) respectively. The number of occluded vessels was positively correlated with both CypA and hsCRP. Also, Serum CypA showed a significant positive correlation with HbA1C.Conclusion Serum CypA can be used as a valuable biomarker for CAD.
- Open Access
- 1 August 2021
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 22 (8) , 2509-2507
Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors
Background: The lack of sensitivity and specificity of existing diagnostic markers like Carbohydrate Antigen 15-3(CA15-3) and Carcinoembryonic antigen (CEA) in breast cancer stimulates the search for new biomarkers to improve diagnostic sensitivity especially in differentiating benign and malignant breast tumors. Expression of Human epididymal protein 4 (HE4) has been demonstrated in ductal carcinoma of the breast tissue. So we tried to evaluate serum HE4 levels as diagnostic marker in breast cancer patients and to comparatively assess serum HE4, CEA and CA15-3 in breast tumor patients both benign and malignant. Methods: Total 90 female subjects were included in the study. We selected 30 breast cancer cases (Malignant group) and 30 benign breast lump cases (Benign group) based on histopathology report. And other 30 were age matched apparently healthy controls (Control group). HE4, CEA and CA15-3 were analysed in serum samples of all subjects by Electrochemiluminiscence immunoassay method. Results: A significant difference in the median (IQR) of HE4 (pmol/l) was identified among malignant, benign and control groups {62.4(52.6-73.7) vs 49.3(39.8-57.4) vs 52.3(50.6-63.3) P=0.0009} respectively. The cutoff value for prediction of breast cancer was determined at >54.5 pmol/l for HE4, with a sensitivity of 73.3%, specificity of 65.3%, whereas cutoff value of CA 15-3 was >21.24 (U/ml) with a sensitivity of 56.7%, specificity of 74.5%. For CEA at cutoff value >0.99 (ng/ml) the sensitivity and specificity were 96.7 % and 62.7% respectively. AUC for HE4, CA15-3 and CEA were 0.725, 0.644 and 0.857 respectively. Conclusion: Our study demonstrated that serum levels of HE4 were significantly higher in malignant group compared to benign and control groups. There is no significant difference between HE4 levels between benign and control groups. These results indicate that HE4 appears as a useful and highly specific biomarker for breast cancer, which can differentiate between malignant and benign tumors.
- 1 August 2021
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 22 (8) , 2509-2507
Open AccessSerum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors
Background: The lack of sensitivity and specificity of existing diagnostic markers like Carbohydrate Antigen 15-3(CA15-3) and Carcinoembryonic antigen (CEA) in breast cancer stimulates the search for new biomarkers to improve diagnostic sensitivity especially in differentiating benign and malignant breast tumors. Expression of Human epididymal protein 4 (HE4) has been demonstrated in ductal carcinoma of the breast tissue. So we tried to evaluate serum HE4 levels as diagnostic marker in breast cancer patients and to comparatively assess serum HE4, CEA and CA15-3 in breast tumor patients both benign and malignant. Methods: Total 90 female subjects were included in the study. We selected 30 breast cancer cases (Malignant group) and 30 benign breast lump cases (Benign group) based on histopathology report. And other 30 were age matched apparently healthy controls (Control group). HE4, CEA and CA15-3 were analysed in serum samples of all subjects by Electrochemiluminiscence immunoassay method. Results: A significant difference in the median (IQR) of HE4 (pmol/l) was identified among malignant, benign and control groups {62.4(52.6-73.7) vs 49.3(39.8-57.4) vs 52.3(50.6-63.3) P=0.0009} respectively. The cutoff value for prediction of breast cancer was determined at >54.5 pmol/l for HE4, with a sensitivity of 73.3%, specificity of 65.3%, whereas cutoff value of CA 15-3 was >21.24 (U/ml) with a sensitivity of 56.7%, specificity of 74.5%. For CEA at cutoff value >0.99 (ng/ml) the sensitivity and specificity were 96.7 % and 62.7% respectively. AUC for HE4, CA15-3 and CEA were 0.725, 0.644 and 0.857 respectively. Conclusion: Our study demonstrated that serum levels of HE4 were significantly higher in malignant group compared to benign and control groups. There is no significant difference between HE4 levels between benign and control groups. These results indicate that HE4 appears as a useful and highly specific biomarker for breast cancer, which can differentiate between malignant and benign tumors.
- 1 December 2019
- Published by Elsevier in Neurochemistry International
- Vol. 131, 104509
Neuron specific enolase as a marker of seizure related neuronal injury
- 1 December 2019
- Published by Elsevier in Neurochemistry International
- Vol. 131, 104509
Neuron specific enolase as a marker of seizure related neuronal injury
- Open Access
- 1 May 2019
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Care
- Vol. 4 (3) , 77-82
Biochemical Characterization of Multiple Myeloma Patients across ISS Stages – A Data Base Workup from a Tertiary Care Hospital in India
Background: Multiple myeloma (MM) is slowly becoming a huge medical burden, challenging the health-care systems of Asian countries. Because of the unavailability of widespread access to various modalities of investigations, and paucity of well compiled data on common presenting features and various laboratory parameters in various stages of MM in India, the diagnosis is usually delayed till complications begin to occur. This study is an attempt to fill this gap and to establish database for future reference. Methods: The study was conducted in a tertiary health care centre over a span of 3 years and 94 patients diagnosed as MM with complete workup including beta2 microglobulin (β2M), bone marrow plasma cell percentage, serum protein electrophoresis, serum and urine Immunofixation and serum Free Light Chains (FLC) were included. The various laboratory parameters were statistically analyzed across ISS stages I, II and III. Results: We found a male to female ratio of 1.47:1. The mean age of patients was 55.5±11.78 yrs. Backache was the most frequent presentation (30%) of the patients followed by generalized weakness (22%). The percentage of plasma cells, hemoglobin, urea, creatinine, uric acid, calcium and β2M showed significant difference across the stages. 38.3% of the patients were in stage III, 29.8% in stage II and 31.9% in stage I. IgGκ type constituted 70%, other fraction being IgGλ (10%), IgMκ (10%), IgAκ (5%) and IgAλ (5%). M band was not seen in 11% of patients.Conclusion(s): The presentation of MM is nonspecific and patient can come with varied presentations at onset. We have biochemically characterized the three stages of MM and this will form a basis for further larger studies on these lines and to develop stage-based algorithms for early and better diagnosis and prognosis of MM.
- 1 May 2019
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Care
- Vol. 4 (3) , 77-82
Open AccessBiochemical Characterization of Multiple Myeloma Patients across ISS Stages – A Data Base Workup from a Tertiary Care Hospital in India
Background: Multiple myeloma (MM) is slowly becoming a huge medical burden, challenging the health-care systems of Asian countries. Because of the unavailability of widespread access to various modalities of investigations, and paucity of well compiled data on common presenting features and various laboratory parameters in various stages of MM in India, the diagnosis is usually delayed till complications begin to occur. This study is an attempt to fill this gap and to establish database for future reference. Methods: The study was conducted in a tertiary health care centre over a span of 3 years and 94 patients diagnosed as MM with complete workup including beta2 microglobulin (β2M), bone marrow plasma cell percentage, serum protein electrophoresis, serum and urine Immunofixation and serum Free Light Chains (FLC) were included. The various laboratory parameters were statistically analyzed across ISS stages I, II and III. Results: We found a male to female ratio of 1.47:1. The mean age of patients was 55.5±11.78 yrs. Backache was the most frequent presentation (30%) of the patients followed by generalized weakness (22%). The percentage of plasma cells, hemoglobin, urea, creatinine, uric acid, calcium and β2M showed significant difference across the stages. 38.3% of the patients were in stage III, 29.8% in stage II and 31.9% in stage I. IgGκ type constituted 70%, other fraction being IgGλ (10%), IgMκ (10%), IgAκ (5%) and IgAλ (5%). M band was not seen in 11% of patients.Conclusion(s): The presentation of MM is nonspecific and patient can come with varied presentations at onset. We have biochemically characterized the three stages of MM and this will form a basis for further larger studies on these lines and to develop stage-based algorithms for early and better diagnosis and prognosis of MM.
- 1 January 2016
- Vol. 17 (5) , 2605-10
Robust Reference Intervals for Serum Kappa and Lambda Free Light Chains from a Multi Centre Study Population from Hyderabad, India: Myeloma Diagnostic Implications.
The International Myeloma Working Group considers the serum free light chain (SFLC) assay to be an adjunct to traditional tests. Apart from the FLC ratio, the absolute values of individual free light chains also are gaining importance as they appear to be more relevant in certain clinical settings. Automated assays are available for their determination. As laboratories put new test systems into use catering to different disease populations, they are required by accreditation and certification bodies to verify or establish performance specifications, including reference intervals (RIs) representative of their population. Our aim was to establish local RIs for SFLC in a multicentre representative healthy population using a robust method. There was no significant relationship between SFLC levels and age, gender and creatinine levels. The 95% RI for κSFLC was 4.81 to 33.86mg/L, for ? SFLC was 5.19 to 23.67mg/L and for κ/?SFLC was 0.36 to 2.33, significantly higher than the values given by the manufacturer. The κ/? SFLC ratio at 2.23, covering 100% of the data, showed 72% sensitivity (95% CI=39.0 - 94.0), 100% specificity (95% CI=71.5 - 100.0), 100% PPV (95% CI=21.5 - 100.0), 95% NPV (95% CI=75.4 - 99.9), and 79% accuracy (95% CI=56.0 - 93.0). In the patient group, kit RI for κ /? SFLC ratio classified 45.5% (n=5) as positive vs 9.1% (n=1) positive by the study RI, while the kit RI for kappa FLC classified 90.9% (n=10) as positive vs 54.5% (n=6) , indicating increased probability of false positive test results with the kit RI when applied to our patient population. Appropriate and specific reference intervals and criteria values result in fewer false-positive and false-negative results which means fewer wrong or missed diagnoses.
- 1 January 2016
- Vol. 17 (5) , 2605-10
Robust Reference Intervals for Serum Kappa and Lambda Free Light Chains from a Multi Centre Study Population from Hyderabad, India: Myeloma Diagnostic Implications.
The International Myeloma Working Group considers the serum free light chain (SFLC) assay to be an adjunct to traditional tests. Apart from the FLC ratio, the absolute values of individual free light chains also are gaining importance as they appear to be more relevant in certain clinical settings. Automated assays are available for their determination. As laboratories put new test systems into use catering to different disease populations, they are required by accreditation and certification bodies to verify or establish performance specifications, including reference intervals (RIs) representative of their population. Our aim was to establish local RIs for SFLC in a multicentre representative healthy population using a robust method. There was no significant relationship between SFLC levels and age, gender and creatinine levels. The 95% RI for κSFLC was 4.81 to 33.86mg/L, for ? SFLC was 5.19 to 23.67mg/L and for κ/?SFLC was 0.36 to 2.33, significantly higher than the values given by the manufacturer. The κ/? SFLC ratio at 2.23, covering 100% of the data, showed 72% sensitivity (95% CI=39.0 - 94.0), 100% specificity (95% CI=71.5 - 100.0), 100% PPV (95% CI=21.5 - 100.0), 95% NPV (95% CI=75.4 - 99.9), and 79% accuracy (95% CI=56.0 - 93.0). In the patient group, kit RI for κ /? SFLC ratio classified 45.5% (n=5) as positive vs 9.1% (n=1) positive by the study RI, while the kit RI for kappa FLC classified 90.9% (n=10) as positive vs 54.5% (n=6) , indicating increased probability of false positive test results with the kit RI when applied to our patient population. Appropriate and specific reference intervals and criteria values result in fewer false-positive and false-negative results which means fewer wrong or missed diagnoses.
- Open Access
- 5 February 2014
- Published by Wiley in Journal of Biomarkers
- Vol. 2014, 1-9
Diagnosis of Non-ST-Elevation Acute Coronary Syndrome by the Measurement of Heart-Type Fatty Acid Binding Protein in Serum: A Prospective Case Control Study
A prospective case control study was undertaken to evaluate the diagnostic performance of serum heart-type fatty acid binding protein (HFABP) in comparison to cardiac TnT and TnI in 33 patients admitted with chest pain, diagnosed as NSTE-ACS (non ST elevation acute coronary syndrome) and 22 healthy controls. Area under the receiver operating curve (AUC) was highest for H-FABP (AUC 0.79; 95% CI 0.66–0.89) versus cTnI (AUC 0.73; 95% CI 0.59–0.84) and cTnT (AUC 0.71; 95% CI 0.57–0.83). The H-FABP level above 6.5 ng/mL showed 56.7% (CI 37.4–74.5) sensitivity, 0.5 (95% CI 0.3–0.7) negative likelihood ratio (−LR), 100% (CI 84.6–100.0) specificity, and 100% (CI 79.4–100.0) positive predictive value (PPV), 62.9% (CI 44.9–78.5) negative predictive value (NPV). cTnI level above 0.009 μg/L had 40% (CI 22.7–59.4) sensitivity, 0.6 (95% CI 0.4–0.8) −LR, 100% (CI 84.6–100.0) specificity, 100% (CI 73.5–100.0) PPV, and 55% (CI 38.5–70.7) NPV. cTnT showed 46.7% (CI 28.3–65.7) sensitivity, 0.5 (95% CI 0.4–0.7) −LR, 100% (CI 84.6–100.0) specificity, 100% (CI 76.8–100.0) PPV, and 57.9% (CI 40.8–73.7) NPV at level above 9 μg/L. +LR were 12.5 (95% CI 1.8–86.8), 1.7 (95% CI 1.0–3.0), and 1.2 (95% CI 0.8–1.9) for H-FABP, cTnI, and cTnT respectively. In conclusion measurement of H-FABP is a valuable tool in the early diagnosis of patients with chest pain (6–8 hrs) and seems to be a preferred biomarker in the differential diagnosis of NSTE-ACS. More studies are needed to determine whether serum H-FABP further improves diagnostic performance.
- 5 February 2014
- Published by Wiley in Journal of Biomarkers
- Vol. 2014, 1-9
Open AccessDiagnosis of Non-ST-Elevation Acute Coronary Syndrome by the Measurement of Heart-Type Fatty Acid Binding Protein in Serum: A Prospective Case Control Study
A prospective case control study was undertaken to evaluate the diagnostic performance of serum heart-type fatty acid binding protein (HFABP) in comparison to cardiac TnT and TnI in 33 patients admitted with chest pain, diagnosed as NSTE-ACS (non ST elevation acute coronary syndrome) and 22 healthy controls. Area under the receiver operating curve (AUC) was highest for H-FABP (AUC 0.79; 95% CI 0.66–0.89) versus cTnI (AUC 0.73; 95% CI 0.59–0.84) and cTnT (AUC 0.71; 95% CI 0.57–0.83). The H-FABP level above 6.5 ng/mL showed 56.7% (CI 37.4–74.5) sensitivity, 0.5 (95% CI 0.3–0.7) negative likelihood ratio (−LR), 100% (CI 84.6–100.0) specificity, and 100% (CI 79.4–100.0) positive predictive value (PPV), 62.9% (CI 44.9–78.5) negative predictive value (NPV). cTnI level above 0.009 μg/L had 40% (CI 22.7–59.4) sensitivity, 0.6 (95% CI 0.4–0.8) −LR, 100% (CI 84.6–100.0) specificity, 100% (CI 73.5–100.0) PPV, and 55% (CI 38.5–70.7) NPV. cTnT showed 46.7% (CI 28.3–65.7) sensitivity, 0.5 (95% CI 0.4–0.7) −LR, 100% (CI 84.6–100.0) specificity, 100% (CI 76.8–100.0) PPV, and 57.9% (CI 40.8–73.7) NPV at level above 9 μg/L. +LR were 12.5 (95% CI 1.8–86.8), 1.7 (95% CI 1.0–3.0), and 1.2 (95% CI 0.8–1.9) for H-FABP, cTnI, and cTnT respectively. In conclusion measurement of H-FABP is a valuable tool in the early diagnosis of patients with chest pain (6–8 hrs) and seems to be a preferred biomarker in the differential diagnosis of NSTE-ACS. More studies are needed to determine whether serum H-FABP further improves diagnostic performance.